Point State Capital LP Bio N Tech Se Transaction History

Point State Capital LP

6 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2022 May 13, 2022	SELL	$126.25 - $231.85 $493,385 - $906,069	-3,908 Closed	0 $0
Q4 2021 Feb 11, 2022	BUY	$216.64 - $362.52 $88,389 - $147,908	408 Added 11.66%	3,908 $1.01 Million
Q3 2021 Nov 15, 2021	SELL	$205.93 - $447.23 $1.34 Million - $2.91 Million	-6,500 Reduced 65.0%	3,500 $955,000
Q2 2021 Aug 13, 2021	SELL	$113.32 - $241.49 $2.01 Million - $4.27 Million	-17,700 Reduced 63.9%	10,000 $2.24 Million
Q1 2021 May 14, 2021	BUY	$85.73 - $119.5 $1.3 Million - $1.82 Million	15,200 Added 121.6%	27,700 $3.03 Million

Q4 2020 Feb 16, 2021	BUY	$72.71 - $129.54 $908,874 - $1.62 Million	12,500 New	12,500 $1.02 Million

327

40.4M

1.31M

1.37M

Ticker BNTX
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 242,684,992
Market Cap $19.4B
Description
BioNTech SE, a biotechnology company, develops and commercializes immunotherapies for cancer and other infectious diseases. The company is developing FixVac product candidates, including BNT111, which is in Phase II clinical trial for advance melanoma; BNT112 that is in Phase I/IIa clinical trial for prostate cancer; BNT113, which is in Phase II...

Get notified when there are updates to the investment portfolio of Point State Capital LP, based on Form 13F filings with the SEC.

Stay updated on Point State Capital LP with notifications on news.